Calcimedica (CALC) director Roberts buys $6k in shares

Published 28/06/2025, 00:40
Calcimedica (CALC) director Roberts buys $6k in shares

Eric W. Roberts, a director and chief business officer at CalciMedica, Inc. (NASDAQ:CALC), recently purchased 4,500 shares of common stock. The transaction, which occurred on June 26, 2025, involved a purchase at a weighted average price of $1.4406 per share, for a total value of $6,482. Prices ranged from $1.43 to $1.4499.

Following this transaction, Roberts directly holds 164,706 shares. He also indirectly holds 32,823 shares through FMTC Custodian - Roth IRA FBO Eric W. Roberts, 49,894 shares by Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA, 10,661 shares by IRA Financial Trust Company CFBO Eric W. Roberts, 356,989 shares by Valence Investments SPV IV, LLC, 66,228 shares by Valence Investments SPV V, LLC and 316,109 shares by Valence Investments SPV VI, LLC.

The purchase was reported in a Form 4 filing with the Securities and Exchange Commission. InvestingPro subscribers can access 8 additional key insights about CalciMedica’s financial health, valuation, and market performance to make more informed investment decisions.

In other recent news, CalciMedica reported earnings per share of ($0.33) for the fourth quarter and ($1.22) for the full year 2024. These figures were slightly below H.C. Wainwright’s estimates but exceeded consensus estimates. The company maintains a pro-forma cash balance of approximately $28.4 million, which is expected to support operations into mid-2026. CalciMedica is actively enrolling participants in its Phase 2 KOURAGE trial for acute kidney injury, with results anticipated by the end of 2025. The company also plans to initiate a Phase 3 study for Auxora in treating acute pancreatitis by the end of 2025, pending additional funding. Following a merger, CalciMedica appointed Baker Tilly as its new accounting firm, replacing Moss Adams. The transition was smooth, with no disagreements reported between the company and the former firm. H.C. Wainwright reaffirmed its Buy rating and $16 price target for CalciMedica, citing ongoing clinical developments and financial stability as key factors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.